Recommendations for Aromatase inhibitors as adjuvant endocrine therapy for post-menopausal women with hormone receptor-positive early breast cancer

January 2006 | Incorporates published evidence to May 2005

Guideline Topic: Early breast cancer
Cancer Types: Breast cancer
Document Satus: Rescinded
This resource is 10 years or older and has been rescinded by Cancer Australia. It is available to the public for research and reference purposes only. Cancer Australia assumes no legal liability or responsibility for errors or omissions contained within.

To provide statements and recommendations, based on the best available evidence, about the use of aromatase inhibitors as adjuvant endocrine therapy for post-menopausal women with hormone receptor-positive early invasive breast cancer.

A clinical practice guideline developed by the National Breast Cancer Centre (NBCC)*

This document supplements guideline recommendation 19 about the use of tamoxifen for the management of post-menopausal women with hormone receptor-positive early breast cancer contained in the NBCC* Clinical Practice Guidelines for the Management of Early Breast Cancer, 2nd edition, 2001 (page 9).

Incorporates published evidence to May 2005

Endorsed by:

  • The Faculty of Radiation Oncology - The Royal Australian and New Zealand College of Radiologists
  • The Royal Australasian College of Physicians
  • The Royal Australasian College of Surgeons

ISBN Print: 1741270103
ISBN Online: 1741270111
CIP: 616.99449061
© Cancer Australia 2011

* In February 2008, National Breast Cancer Centre (NBCC), incorporating the Ovarian Cancer Program, changed its name to National Breast and Ovarian Cancer Centre (NBOCC). In July 2011, NBOCC amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.

View guideline »